BVX002 / BiVictriX Therap - LARVOL DELTA

BiVictriX Therapeutics shares promising ovarian cancer data from second asset (Proactiveinvestors) - "BiVictriX Therapeutics PLC...has reported positive initial results from preclinical testing of its lead solid tumour treatment, BVX002, targeting ovarian cancer....In a mouse model, the drug showed tumour growth reductions between 78.3% and over 100%. Shrinkage of up to 63.1% was observed at mid and high doses. The drug was administered weekly over four doses and was well tolerated even at the highest levels, with no major side effects....BiVictriX plans to use the data from this study, along with further research, to file an Investigational New Drug (IND) application with the US Food & Drug Administration."

Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

BiVictriX says Innovate UK grant will help fast track development of second asset (Proactiveinvestors) - "BiVictriX Therapeutics PLC...has received a £370,000 grant from the government-backed Innovate UK agency to accelerate the development of its second therapeutic programme, BVX002, an antibody drug conjugate (ADC) targeting ovarian cancer. This non-dilutive funding will allow the company to fast-track preclinical development of the programme, including studies and preparation for selecting a clinical lead candidate. The 18-month project will focus on two primary objectives: selecting the optimal linker/payload and therapeutic format combination and assessing in vivo efficacy, selectivity, and safety."

Financing • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor